Significant Ki-67 protein suppression in HR-positive, HER2-negative breast cancer was seen among patients treated with ...

It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in HR+ HER2-ve Breast ...

A powerful, three-drug therapy for aggressive advanced breast cancer doubles the length of time before the cancer progresses, ...

Genentech Executive Levi Garraway, MD, PhD, called the approval "an important new first-line option for people living with HR+ breast cancer with a PIK3CA mutation" in a company press release.

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.

Adam Brufsky, MD, PhD, professor of medicine at the University of Pittsburgh School of Medicine; Megan Kruse, MD, breast medical oncologist at Cleveland Clinic; and Ruta Rao, MD, professor of medicine ...

HR+/HER2- is the most common subtype, accounting for approximately 70% of all breast cancers, and more than 40% of these are diagnosed in stage II or III 8-10.

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Breast cancer is the most commonly diagnosed cancer in Europe. HR+/HER2- is the most common subtype, accounting for approximately 70% of all breast cancers, and more than 40% of these are diagnosed in ...